A Multicenter, Randomized, Double-blind, Placebo-controlledTrial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously, in Methotrexate-naive Subjects With Active Rheumatoid Arthritis.

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlledTrial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously, in Methotrexate-naive Subjects With Active Rheumatoid Arthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Golimumab (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms GO-BEFORE
  • Sponsors Centocor
  • Most Recent Events

    • 12 Jun 2017 Pooled results from GO-BEFORE and GO-FORWARD studies (n=470) published in the Annals of the Rheumatic Diseases.
    • 10 Jun 2017 Biomarkers information updated
    • 01 Nov 2016 Results of 5-year safety data from five trials (GO-BEFORE, GO-FORWARD, GO-AFTER, GO-REVEAL, GO-RAISE) published in The Journal of Rheumatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top